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1. Introduction 
A substantial amount of scientific documentation is mounting for the significance of the 
gastrointestinal microbiota (gut or GI microbiota) on human health. In addition to the 
obvious connection between the gut microbiota and inflammation in the colon (leading to 
IBD, IBS and possibly colon cancer), recent articles have highlighted the not-so-obvious 
connection between the gut microbiota and the brain (Heijtz et al., 2011)) and cardiovascular 
system (Wang et al., 2011).  
Despite several major breakthrough discoveries of the importance of the gut microbiota in 
human health, this information has not yet been transformed into diagnostic or therapeutic 
approaches. A major bottleneck in the gut microbiota diagnostics is the reproducibility and 
throughput of the analytical approaches used.  
Since we do not know the growth conditions for most gut bacteria, traditional cultivation 
based analysis of bacteria cannot be used for a comprehensive overview of the gut 
microbiota. Currently, quantitative PCR are quite extensively being used to detect the 
presence of specific pathogens. However, since the gut microbiota is complex and 
contains hundreds of different microbes, such technology does not hold the promise to be 
used as a general analysis tool to monitor changes in the gut microbiota that affect health 
conditions. The current focus in human gut microbiota screenings are based on 
explorative deep sequencing. It is expected that it will take considerable time and further 
development before sequencing of the gut microbiota could become a routine diagnostic 
tool. However, since the human gut microbiota is getting more thoroughly characterized, 
it is time to look for more targeted approaches rather than the current explorative 
screenings.  
The most widely applied targeted approach to describe microbial diversity are by probes 
targeting the gene encoding 16S ribosomal RNA. This gene is ancient, universally 
distributed and comprise highly conserved sequence domains interspersed with more 
variable regions (Woese, 1987). The conserved regions provide information for 
classification of higher taxa, while the variable regions can be used for differentiation 
between closely related species. An average bacterial 16S rRNA molecule has a length of 
approximately 1 500 nucleotides, making it experimentally manageable by e.g. PCR 
amplification.  
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The first step in 16S rRNA gene microbiota analyses is to purify DNA from all bacteria 
present in a sample without introducing bias due to e.g. differential lysis or recovery. 
Subsequent to DNA purification, all bacterial 16S rRNA genes in the samples are amplified 
using primers targeting generally conserved regions in the 16S rRNA gene. The ratio 
between 16S rRNA gene copies for different bacteria is (in theory) conserved during the 
PCR amplification process. 
Currently the most widely used approach to analyze 16S rRNA gene diversity is through 
next generation sequencing (Kunin et al 2010). The depth of the information that can be 
obtained form such sequencing efforts are dependent on the number of reads that are being 
done.  
An alternative approach is the use of high-density microarrays based on 16S rRNA sequence 
variations. These approaches are explorative, and intended for discovery rather than 
diagnostics. A major challenge with traditional 16S rRNA gene microarrays is probe 
specificity, and cross-reactivity between closely related species (Cox et al 2010). For 
microarrays, this challenge has recently been addressed by tilling probes covering the 
variable region of the 16S rRNA gene (Rajilic-Stojanovic et al 2009). The principle by tilling 
is that a large number of overlapping probes cover the region of interest, with the combined 
probe signals providing a relatively good signal-to-noise ratio. Both for next generation 
sequencing and microarray analysis, a comprehensive data analysis of the information is 
required in order to obtain interpretable results. 
A more direct approach for characterizing the gut microbiota is the use of highly specific 
single nucleotide primer extension (SNuPE) probes (Eggesbo et al 2011).The high specificity 
of the SNuPE assay is obtained by DNA polymerase based incorporation of a labeled 
dideoxynucleotide (Syvanen et al 1990). The SNuPE probes are constructed so that the 
probes hybridize adjacent to discriminative gene positions. If the target bacterium is present, 
a labeled dideoxynucleotide is incorporated by the polymerase.  
A technology platform have been developed that can readily be applied to analyze the gut 
microbiota based on the SNuPE principle. The method – called GA-map™ (Genetic 
Analysis’ Microbiota Analysis Platform) - has already demonstrated its usefulness in 
applications for assessing various disease states based on analysis of the composition of the 
gut microbiota. 
Here, we discuss the possibility of using a novel comprehensive targeted approach for 
quantifying the inhabitants of the human gut microbiota in disease diagnostics. 
2. Requirements for a gut microbiota test 
The general requirements for a gut microbiota test is (i) simple sample collection, (ii) 
comprehensive, (iii) reproducible, (iv) high-throughput and (v) affordable. In addition, the 
test must deliver results that can be interpreted and be relevant to disease. 
There are still major challenges with all these requirements. Most methods developed for 
research are actually not well documented, and promises far more than the methods in 
reality can deliver. A current example of this is the emergence of the next generation 
sequencing approaches. For instance, it is now being realized that these techniques inflate 
diversity measures (Kunin et al 2010). New software tools have been developed to reduce 
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this inflation of diversity, but it is still uncertain if the number of different Operational 
Taxonomic Units (OTUs) obtained by next generation sequencing techniques gives a correct 
representation of the actual number of different bacteria present in the sample.  
Perhaps the largest challenge in gut microbiota diagnostics is the establishment of the 
correlation between microbiota patterns and disease. Since the characterization of the gut 
microbiota is in its infancy, there are not many diseases that have actually been 
characterized with respect to specific dysbiosis of the gut microbiota. Furthermore, since the 
analysis represent patterns rather than single bacteria, new diagnostic principles must also 
be implemented. 
Diagnostic approaches related to dysbiosis of the gut microbiota have until now been 
dominated by culture dependent techniques which only detect a minor portion of the true 
diversity. Doctors used to such techniques may find it challenging to adapt knowledge 
about non-cultivable bacteria in their diagnostics because that would include bacteria that 
they are not familiar with. 
We have for instance found that the clostridal family Lachnospiraceae is the most stable and 
dominant phylogroup in the human gut (Sekelja et al., 2011).This phylogroup has been 
overlooked by the traditional cultivation dependent techniques, probably because it is 
strictly anaerobic and that it has special growth requirements that are difficult to simulate 
on plates. 
3. Function vs phylogeny of gut bacteria 
A long standing debate is how well functionality of bacteria in the gut correlates to 
phylogeny. There are recent reports suggesting that the function of gut bacteria is a 
relatively stable feature, while the microbiota composition is unstable (Turnbaugh et al., 
2009).  
Although functions cannot directly be deduced from the gut microbiota 16S rRNA gene 
analyses, correlations between gut microbiota phylogenetic composition and function can be 
established. We have recently addressed this issue by mapping functions onto a 
phylogenetic map as illustrated in Figure 1. As seen in this figure, there are good 
correlations between functions and phylogeny, with different functions being clustered in 
different phylogroups. 
The take home message from this analysis is that the phylogenetic framework can be used to 
deduce the probability of functions in the gut microbiota, and aid in identifying functions 
through other targeted approaches. Still, however, our knowledge about the correlations 
between function and phylogeny is limited. The current major genomic sequencing efforts 
will aid in these investigations. It will be particularly interesting to determine which 
functions follow a phylogenetic distribution pattern, and which do not.  
For genes located on mobile elements, such as those encoding antibiotic resistance, an 
important aspect would be to determine the host range of the mobile elements. For instance, 
given that there are antibiotic resistance genes present on mobile elements in the commensal 
microbiota with a host range that include pathogens, there will be a severe risk that the 
antibiotic resistance genes can be transferred to the pathogen.  
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Fig. 1. Properties of gut bacteria in a phylogenetic framework. The PCA biplots represent the 
16S rRNA phylogenetic relatedness between the bacteria, while the green circles represent 
different functions for the different panels. The six panels represent six different functional 
groups.  
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4. Diseases with established correlation to the gut microbiota 
Necrotizing enterocolitis (NEC) (Wang et al 2009) and inflammatory bowels disease (IBD) 
(Frank et al 2007, Nell et al 2010) are two diseases that have a recognized established link to 
the gut microbiota. 
NEC is a severe disease affecting preterm infants with a high mortality. About 10% of 
infants with a birth weight below 1500 g develop NEC, with mortality rate is as high as 30%. 
It has been suggested that this disease is associated with a reduced diversity of the gut 
microbiota (Wang et al 2009). Both due to the impact of the test, and because the preterm 
infant gut microbiota is relatively simple, NEC is an attractive target for developing a 
human gut microbiota test.  
IBD represents a collection of diseases associated with gut inflammation. It has two main 
sub forms: Crohn’s Disease (CD) and Ulcerative colitis (UC). Disturbance of the normally 
stable GI microbiota are predicted to adversely affect the health of the host (Frank, et al., 
2007). Studies of experimental animal models of IBD reveal that germ-free animals show 
few signs of inflammation; experimental colitis is exhibited only when the animal is exposed 
to natural microbial communities. Likewise human studies have shown a response of IBD 
patients to antibiotic and probiotic treatment (Hecht, 2008). In CD patients inflammation 
most commonly appears in the gut locations where bacterial concentrations are high. 
Furthermore, diversion of the fecal stream from the lumen is associated with improvement 
of the inflammation, indicating a role for bacteria in the IBD pathogenesis (Baker, Love, & 
Ferguson, 2009). Taken together, there are relatively good evidence for a correlation between 
IBD and the gut microbiota.  
5. Diseases with suspected correlation to gut microbiota 
There is a very wide range of diseases that have been suggested correlated to the gut 
microbiota. Among these are diabetes, cardiovascular diseases, rheumatism, metabolic 
syndrome and obesity (Wang et al. 2011, Wen et al., 2008, Ley et al., 2006). Common for 
most of these diseases is the correlation to some form of underlying inflammation. Thus, 
imbalance in the gut microbiota could be a common underlying factor that triggers 
inflammation. Still, detailed knowledge is lacking about such potential correlations.  
Future knowledge building with respect to microbiota composition could open new 
diagnostic possibilities for these diseases, which all have major impacts on human health. 
Gut microbiota diagnostics may also help in understanding the etiology of the disease, 
which potentially could help in developing therapeutic approaches. 
The perhaps most surprising correlation to the gut microbiota are cardiovascular disease 
(Wang et al. 2011). There were relatively strong correlations between microbial metabolites 
and atherosclerotic disease. Gut microbiota diagnostic in this field could potentially have 
major impacts on human health.  
6. Gut micobiota diagnostic for diffuse conditions 
Major diseases with more diffuse symptoms such as irritable bowels disease (IBS) (Salonen 
et al 2010) and depression (Maes et al 2009) could be targets for development of future 
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diagnostics. These are diseases representing enormous burden and costs to society. If these 
diseases can be linked to some kind of gut microbiota disorders, then there may also be 
potential for intervention and treatment.  
Discomfort such as abdominal pain, flatulence and bloating affect our everyday life. It has 
recently been shown correlation between these discomforts and specific gut bacteria 
(Jalanka-Tuovinen et al., 2011). Although not life threatening, the quality of life can be 
severely reduced by these discomforts. Diagnosis of the gut microbiota could potentially 
help in dietary interventions. 
Although the severity of IBS is not pronounced, 10% - 20% of people in the Western world 
suffer from this (Maxion-Bergemann et al 2001). Therefore, a diagnostics for this condition 
could have major impact, given the potential for advice that would increase the quality of 
life through reducing discomforts. 
7. Stratification of patients with respect to gut microbiota in clinical trials 
It has recently been discovered that the gut microbiota plays a major role in the human 
metabolome (Nicholson et al 2005), and that the effects of drugs can be dependent on the gut 
microbiota (Clayton et al 2009). Combined with recent evidence that the human microbiome 
may consist of only three enterotypes (Arumugam et al 2011), diagnostics of such 
enterotypes is expected to provide important information with respect clinical trials. 
Enterotypes represent clusters of bacteria with a high frequency of co-occurrence, 
suggesting different states of the microbiota with different functionalities. There are several 
evidences for gut microbiota metabolism of important drugs, such as drugs against 
Alzheimer (Pieper et al., 2009) 
Combined with the enterotype knowledge we believe that stratification will be a highly 
interesting field for gut microbiota diagnostics. This will be in line with the recent 
developments of personalized drugs –drugs adapted to individuals. Clearly, a major part of 
defining an individual would be the composition of gut microbiota. Information about the 
gut microbiota may therefore help to increase the success rate of clinical trials. 
8. Manipulation of gut microbiota with pro- and prebiotics 
The diet plays a major role in stratifying the gut microbiota (Muegge, 2011). This gives 
promise for food related gut microbiota perturbations. Manipulation of the gut microbiota 
through the diet is an old concept, either through probiotic live bacteria, or through 
prebiotic oligosaccharides.  
Even though there is a range of products on the marked, there have been challenges in 
documenting the effect of these products. Diagnostic products that will help in 
substantiating the potential health claims would be of great benefit to the food industry. A 
main reason for the lack of documentation could actually be the lack of proper tools to 
describe the microbiota, rather than that the products have no effect.  
Given proper documentation, the marked for pro- and prebiotics is very large. In particular, 
documentation that can be used in marketing would have a high commercial value. New 
diagnostic approaches could also potentially enable the discovery of new pro- and prebiotic 
products.  
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9. GA-map tecnology platform in gut microbiota diagnostics 
The GA-map platform has given rise to a pipeline of assays for analysis of disease based on 
the microbiota composition. This platform includes a DNA purification module, a module 
for probe design, a patent protected approach for the actual gut microbiota screening, in 
addition to a diagnostic database. The GA-map assay will help to utilize information in the 
gut microbiota for diagnostic purposes. 
An outline of the GA-map platform for gut microbiota diagnostics is illustrated in Figure 2. 
The platform can be used to assess health conditions of individuals based on the 
composition of the gut microbiota. In addition, it can serve both the the pharmaceutical 
industry and governmental health authorities in epidemiological population screenings and 
clinical trials. In addition, the technology can be used for early detection of undesirable 
conditions in the gut that can be corrected before the illnesses are manifested. The core 
aspects of the technology was developed and patented at the University of Oslo in 1998 (US 
patent # 6 617 138 Nucleic Acids Detection Methods). The technology has since then been 
refined at Nofima Mat (Matforsk). Currently the technology is patented worldwide and 
Genetic Analysis AS has been set up to commercialize the technology. 
A high throughput analysis platform based on this technology will make it possible to gain 
greater understanding of the relationship between the composition of the gut microbiota 
and health, as well as being used as a diagnostic and prognostic tool in the future. 
9.1 GA-map array 
Probe labeling is based on the minisequencing principle, where a DNA polymerase extends 
the probe with a single labeled dideoxy nucleotide (Syvannen et al., 1990). In the GA-map 
assay several probes are labeled simultaneously, with the detection by reverse hybridization 
to the complementary strands spotted on to a solid phase (Vebo et al., 2011). This process is 
illustrated in Figure 3. The probes are constructed so that the probes hybridize adjacent to 
discriminative gene positions. If the target bacterium is present then a labeled 
dideoxynucleotide is incorporated by the polymerase. This is illustrated in Figure 3A. The 
solid phase (i.e. microarray or beads) is used to separate the probes by hybridization to their 
respective complementary sequences attached to the solid phase, which is illustrated in 
Figure 3B (exemplified by an array). 
9.2 Probe design  
There are several steps in the GA-map array process that can lead to wrong patterns if the 
probes are not properly designed. The probes may bind to the wrong target, and be labeled 
that way. Furthermore, the probes may be labeled by using itself as a target, or another 
probe as target. Finally, the probes may bind to the wrong spots on the array. Successful 
application of the GA-map assay requires therefore the application of a probe design 
software that takes into account many of the potentially unwanted reactions mentioned 
above, leading to false results. 
The probe design is based on a novel way of bacterial classification based on 16S rRNA gene 
sequences. Rather than classifying bacteria by traditional phylogenetic tree-based 
approaches, the bacteria are classified in a coordinate system (Rudi et al., 2006). The benefit 
of this approach is both that very large numbers of bacteria can be analyzed, and that 
phylogroups are easily identified for probe design. This is illustrated in Figure 4. 
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Fig. 2. GA pipeline. This figure illustrates the GA core technology and pipeline. Based on 
signatures in the 16S rRNA gene sequences GA probes are designed and evaluated in silico 
using the GA probe design tool. The GA analysis involves automated sample preparation 
combined with array hybridization . The whole information flow is stored in the GA 
database including the information about sample preparation and storage. The results to the 
end user are in the form of a direct description of the microbiota with respect to 
consequences for health and disease. Using this proprietary GA technology, a GA array is 
obtained, giving a specific “fingerprint” of each persons gut microbiota. 
www.intechopen.com
 
Gut Microbiota in Disease Diagnostics 
 
109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Schematic outline of the GA map assay(A) Illustration of the SNuPE principle. An 
unlabelled probe hybridizes adjacent to a discriminative guanine on the complementary 
DNA strand. A DNA polymerase single-base extends the probe with a labeled cytosine 
dideoxy nucleotide. (B) Illustration of array hybridization of SNuPE labeled probes. Three 
probes are illustrated by green - , red – and blue bars. The green and the red probe are 
labeled. The probes are hybridized to their complementary sequences on an array as 
illustrated with the squares. The green and red probes will give a signal on the array due to 
the label, while the blue probe will not give a signal since it is not labeled.  
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Fig. 4. Illustration of coordinate based classification of bacteria related to IBD. Each point in 
the plot represent a 16S rRNA gene sequence from a single bacterium. The distances 
between the points reflect the relatedness between the bacteria. For illustration, the points 
labeled green are target organisms for probe design, while those labeled red are non-target 
organisms.  
After a set of probes have been constructed, the probes are evaluated with respect to if they 
will self-label (Figure 5A), whether they can cross-label (Figure 5B), or whether they will 
bind to a wrong spot on the array (Figure 6C). This bioinformatics evaluation is crucial for 
the successful construction of functional probe-set based on the GA-map technology (Vebo 
et al., 2011).  
Validation of probes constructed with the probe design software have shown a high success 
rate (Vebo et al., 2011). Prior to the development of the software, probes were identified 
manually from multiple sequence alignments. The conclusion from the manual 
constructions, however, was that these probes did not perform satisfactory, and that there 
were too many considerations when performing this probe construction to make it possible 
to do manually. 
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Fig. 5. Illustration of steps in probe evaluation. (A) The first step is to evaluate whether the 
probe will self label. A high value here indicates a high risk of self labeling. (B) The next step 
is to evaluate the potential of cross-labeling. A color code is used to illustrate the risk of 
cross-labeling. High values indicate high risk. (C) The final evaluation is whether the probe 
will bind to the right spot on the array. The red diagonal line indicates correct hybridization, 
while red squares outside the diagonal would indicate wrong hybridization.  
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9.3 Application of the GA-map array to describe the temporal development of the gut 
microbiota in infants 
We have evaluated the recently developed GA-map infant microarray as a high throughput 
assay for screening of the gut microbiota. We analyzed 216 faecal samples collected from a 
cohort of 47 infants from 1 day until 2 years of age. To test the predictive ability of the assay 
we asked the question whether we could predict the age of the infants based on the 
microarray data. 
The Prevention of Allergy Among Children in Trondheim (PACT) study is a large 
population based intervention study in Norway focused on childhood allergy (Oyen et al., 
2006). The samples included here is a subset from the PACT study. Mechanical lysis was 
used for cell disruption, and an automated magnetic bead-based method was used for DNA 
purification. The approach is previously described by Skånseng et al. (2006) 
We experienced that the primer pairs commonly used for amplification of the full-length 16S 
rRNA gene showed poor amplification of bifidobacteria. To circumvent this problem we 
developed a novel primer pair to obtain a near full-length 16S rRNA universal amplicon. 
The amplicon was evaluated both theoretically based on sequences in the RDP II database, 
and experimentally for bacterial species expected in the infant gut. We found that all the 
currently known infant gut bacteria were amplified with this new, optimized primer pair. A 
primer pair that is able to representably amplify the 16S rRNA gene from all the bacteria 
present in the sample is critical for proper analysis of the sample. 
9.3.1 Temporal development of the infant gut microbiota 
Based on signals from the GA-map array we determined the temporal development of the 
gut microbiota in the infants. These results are pressented in Figure 6. 
The prevalence data showed that proteobacteria and lactobacilli reached a maximum 
between one month and one year, while the bacteroides subgroup containing B. fragilis 
reached a maximum after one to two years. Surprisingly, we found a high prevalence of 
bifidobacteria for infants older than one month. This is in contrast to another recent 
microarray screening of the infant gut microbiota, where they found that bifidobacteria were 
underrepressented (Palmer et al., 2007). This demsontrates the importance of using an 
optimal primer pair in the amplification of the 16S rRNA gene. 
9.3.2 Modelling age as a function of the microbiota composition 
We used the temporal information in the gut microbiota to determine if it is possible to 
describe age as a function of the composition. This was done using generalized additive 
models (GAM).  
The following function was derived: 
age = s(E.coli) + s(Clostridium) + s(Staphylococcus)  
+ s(Bif.breve) + s(Bacteroides.dorei.vulg.theta.frag.) 
The functions s to the data are shown in Figure 7. 
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Fig. 6. The prevalence of the G-map bacteria was determined within age groups. The color 
code indicates the prevalence from absent (white) to present in all samples (black). 
 
 
 
Fig. 7. Bacteria which are important for age prediction. For each bacterium the age 
contribution is a function of probe signal. Adding all the age contributions gives the 
predicted age (see function above). The final panel shows a regression between the observed 
and predicted ages for all the samples in our data. 
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High E. coli and staphylococci abundance predict an early age, while for the bacteroidetes 
and B. breve a medium abundance predicts a high age (Fig. 7 B and D). However, very high 
abundance predicts an early age. The Clostridium probe, on the other hand, shows a 
complex association with age. 
Figure 7 shows that the age can be modelled with high accuracy from the microbiota 
composition.We found that the observed and modelled age gave a squared regression 
coefficient of 0.6. These results show that the development of the human gut microbiota is 
very structured with age, and that it can be predicted. The consequence is that it could 
potentially be possible to determine the normal development of the microbiota in infants, 
and use deviations from the normal pattern in identifying disorders. For instance, from our 
results we can conclude that high levels of staphylococcus for older children would clearly 
indicate some kind of deviation form the normal development, and indicate some kind of 
diseased state.  
9.4 Application and development of the GA-map assay for diagnostic purposes 
We are currently adapting the GA-map assay for detection of the human adult core 
microbiota, as defined by (Arumugam, et al., 2011). This will enable an assay for the normal 
gut microbiota, and in identifying the gut microbiota enterotypes. We foresee that, in 
addition to disease-specific diagnosis, such an assay could potentially be valuable for the 
pharmacutical industry in population stratification in clinical trials. This tool could also be 
used by the food industry to determine whether their pro- prebiotic products have an 
impact on the normal gut microbiota.  
9.4.1 IBD 
Diagnostic of IBD is an important target for the GA-map assay since there are established 
correlations between gut microbiota composition and disease. The intention with the assay 
would be early detection of IBD, and potentially in the following up of IBD treatments. 
Alternatively, it can be used to rule out IBD from IBS patients. In the future, given a causal 
relation between gut bacteria and IBD, knowledge about the microbial composition could be 
used in disease treatment. Preliminary data using a very limited probe-set illustrates that it 
should be possible to develop IBD diagnostics using the GA-map technology (Frøyland, 
2010). The assay is currently being refined by the addition of more probes, and through 
validations on clinical material. Since we are using feces and not mucosal samples in our 
analysis we were surprised to obtain the relatively high specificity for CD.  
9.4.2 NEC 
The GA-map assay is also currently being evaluated for the analysis of NEC. NEC is a very 
severe disease where rapid and precise diagnostics are crucial. As for IDB there are already 
established correlations between gut microbiota and the disease. Furthermore, for this 
disease there are currently no good diagnostic approaches. Preliminary data show promise 
for separation NEC samples from that of controls. The aim is to further improve the assay 
and model in order to develop a prognostic assay for NEC development. Such a test would 
be of great help for pediatricians and neonatologists working with pre-term infants as a 
guide in treatment regimes.  
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Table 1. Single probe GA-map diagnostics of CD (Frøyland, 2010) 
9.4.3 Test for assessing health condition of individuals 
Many medical doctors find that an analysis of a patients gut microbiota is helpful in 
obtaining a more complete picture of the condition of the patient, and thus determining the 
disease state and best treatment. Several such tests exists in the marketplace. The GA-map 
technology is positioned to become a very powerful test for this purpose, with its complex 
probe selection and high through-put capabilities.  
The general process for the application of the GA-map assay for diagnostic purposes is 
illustrated in Figure 8.  
After implementation of the pilot diagnostic assays, new approaches and diseases will be 
implemented under the GA-map umbrella. There will also be a transformation over time 
towards decentralized analyses.  
10. Future directions of gut microbiota diagnostics 
There is currently a major focus on exploring the gut microbiota. This is mainly done 
through the application of explorative techniques such as next generation sequencing. The 
next phase will be the validation where the discoveries are validated using targeted 
techniques such as microarray analyses or quantitative PCR. The final phase will be to 
identify correlations between microbiota and disease that will give some added value  
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Fig. 8. Illustration of the GA-map diagnostic procedure. The GA-map assay will initially be 
offered through centralized service labs. A database covering relationships between profiles 
and disease will constantly be updated based on accumulated information, and a web-based 
interface with the customers will be available.  
through diagnostics. This would open up for various applications of tests for profiling the 
gut microbiota in disease management.  
As the importance of the gut microbiota on health becomes more established and 
recognized, profiling the composition of the gut microbiota will become an important 
diagnostic and prognostic tool in the future. This will give an additional window for health 
professionals to assess the conditions of the patient. 
As technology advances and miniaturization and sophisticated Point-of-Care devises are 
being developed, such comprehensive tests will become easier to perform and more 
affordable. We see at least three areas where such a test would be applied in health care in 
the future: 
1. Disease specific diagnostics 
As discussed in this paper, certain health conditions are related to imbalance in the gut 
microbiota. A test that can correlate imbalances in the gut microbiota to specific health 
conditions will have a value as a diagnostic and prognostic tool. Furthermore, such tests 
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could also act as a general help for physicians in determining the best treatment for 
patients. 
2. Personalized medicine 
Understanding how different bacteria in the gut influences the metabolism of drugs and 
foodstuff, leads to a more personalized, tailor-made drug treatment regime. Since it is 
generally recognized that the composition of the gut microbiota has a profound effect on 
health as well as how foodstuff and drugs are metabolized, a profiling of the gut microbiota 
would constitute an important aspect of the personalized medicine approach. It is expected 
that personal medicine would lead to more effective treatments, as well as cost-saving on 
healthcare budget due to optimizing the drug treatment for each person. 
3. Deviations from each individuals normal flora 
The search for a common core gut microbiota has revealed that each individual has a unique 
and fairly stable microbiota, at least in adults. Therefore, each individual’s own microbiota 
may be the best control for that person. This calls for routine checks where deviations from 
its own “normal” core microbiota will be evaluated. Such a test would also include other 
genetic and physical markers, which combined would give a status of the individual’s 
health condition.  
With future technical development we believe the next generation gut microbiota diagnostic 
will integrate phylogeny and functionality of the gut microbiota. A functionality that is 
particularly relevant is antibiotic resistance. There is currently a major fear for the 
development of multi-resistant pathogens, and that the current treatment regimes with 
broad-spectrum antibiotics will eradicate beneficial bacteria. In this regard targeted narrow 
spectrum antibiotics could be the solution. Narrow-spectrum antibiotics, however, would 
require better diagnostics of the actual disease causing organisms. Therefore, a profiling of 
the gut microbiota may be essential prior to administration of such narrow antibiotics to 
ensure optimal treatment. 
Another aim in treatment of gut microbiota disorders is to restore the diseased gut 
microbiota towards the healthy state. This could be done either through tailor-made 
administration of probiotics, prebiotics and antibiotics, or a combination of these substances. 
Another approach would be to transplant the gut microbiota from close relatives or samples 
from the same individual collected before disease occurs. Such an approach would resemble 
what is currently done for treatment of Clostridium difficile infections where the gut 
microbiota is transplanted from relatives. 
11. Conclusions 
As more data are being generated, the importance of the gut microbiota on health will 
become more recognized. The advancement in characterizing the composition of the gut 
microbiota in humans paves the way for new and better health treatments. The techniques 
used for exploring the gut microbiota and characterizing the functions of the microbiota, 
may not necessarily be the same techniques used to diagnose and monitor treatment of gut 
health related diseases. The GA-map assay is a promising tool for the development of gut 
microbiota diagnostics in routine applications. Such assays has the potential to be set up as a 
high through-put service, and can also be incorporated into smaller Point-of-Care devices, 
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opening up new, exciting applications to health management. A comprehensive and rapid 
characterization of the gut microbiota will be part of the tool-box physicians will use in the 
future to improve diagnosis and treatments of patients.  
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